TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vaccinating Children After Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Cases with ALL:~Inclusion Criteria:~* Diagnosed with standard, high-risk or very-high risk ALL~* Age at diagnosis: ≥1 year of age (age at enrollment: ≥3 years)~* Completed chemotherapy 3 to 12 months prior to enrollment~* No evidence of ALL relapse or secondary malignancy~* No known primary immunodeficiency~* No receipt of pneumococcal or tetanus-containing vaccines since completing chemotherapy~* No history of allergy to any component of PCV13~* Caregiver and/or participant is English or French-speaking and able to provide written informed consent~Exclusion Criteria:~* Infantile ALL~* Evidence of disease relapse or secondary malignancy~* History of underlying primary immunodeficiency~* Transplant recipient~* Received intravenous immunoglobulin (IVIG) within past 9 months or other blood products within the prior 3 months.Children who received PPV23 within 12 months of enrollment will not be eligible to receive PCV13 or PPV23. These children can still participate in the baseline evaluation, receive DTaP-Hib-IPV vaccine, and have tetanus and pertussis serology measured at 2 and 12-15 months post-immunization.~Controls:~Inclusion criteria~* Children 3-18 years of age, age-matched to cases~* Caregiver and/or participant is English or French-speaking and able to provide written informed consent~Exclusion criteria~* History of primary or secondary immunodeficiency including aplastic anemia, malignancy, nephrotic syndrome, malabsorption or severe malnutrition~* Immunosuppressive therapy within 3 months of enrollment (excluding inhaled corticosteroids)~* Received intravenous immunoglobulin (IVIG) within past 9 months or other blood products within the prior 3 months.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: ACTIVE_COMPARATOR): Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
- Healthy Control (Type: NO_INTERVENTION): Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Dutasteride in Treatment of Chronic Prostatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged between 40 and 70 years old, diagnosed with chronic prostatitis based on the presence of pelvic pain for ≥3 months of the preceding 6 months~Exclusion Criteria:~Patients with bacterial prostatitis~* documented site of infection along the urinary tract,~* urinary bladder tumors~* prostate cancer~* previous history of pelvic radiation or chemotherapy were excluded from our study.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dutasteride (Type: ACTIVE_COMPARATOR): Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo.
- Placebo (Type: PLACEBO_COMPARATOR): same form and color of Dutasteride tablet was given at the same regimen to act as a placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have completed 48 weeks in Study 190-201.~* Is willing and able to provide written, signed informed consent. Or, in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorized representative, after the nature of the study has been explained, and prior to performance of research-related procedures.~* Males and females who are of reproductive age should practice true abstinence, defined as no sexual activity, during the study and for 6 months after the study has been completed (or withdrawal from the study). If sexually active and not practicing true abstinence, males and females of reproductive age must use a highly effective method of contraception while participating in the study.~* If female, of childbearing potential, must have a negative pregnancy test at the Screening Visit and be willing to have additional pregnancy tests done during the study.~Exclusion Criteria:~* Has had a loss of 3 or more points in the combined motor and language components of the Hamburg CLN2 rating scale between Baseline of Study 190-201 and the Study Completion visit in Study 190-201 and would not benefit from enrolling in the study in the Investigator's discretion.~* Has a score of 0 points on the combined motor and language components of the Hamburg CLN2 rating scale.~* Is pregnant or breastfeeding, at Baseline, or planning to become pregnant (self or partner) at any time during the study.~* Has used any investigational product (other than BMN 190 in 190-201), or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments.~* Has a concurrent disease or condition that would interfere with study participation, or pose a safety risk, as determined by the Investigator.~* Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) (Type: EXPERIMENTAL): All 190-202 study subjects administered BMN 190 300 mg by continuous Intracerebroventricular (ICV) infusion at a rate of 2.5 mL/hour for approximately 4 hours) every 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Female, ≥ 18 years.~* Histologically confirmed invasive breast cancer.~* Metastatic breast cancer.~* Karnofsky Performance Status ≥60.~* Life expectancy of more than 3 months.~* Subject must have adequate organ function.~* Normal laboratory values: hemoglobin \> 80g/dl, neutrophils \> 2.0×10\^9/L, platelets \> 80×10\^9/L, serum creatinine \< upper limit of normal (ULN), serum bilirubin \< ULN, ALT and AST \< 2.5×ULN, AKP \< 5×ULN.~* Negative serum pregnancy test for women with childbearing potential.~* Good conditions for infusion and willing to have phlebotomy throughout whole study.~* Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy for more than 28 days.~* Have at least one target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* No prior use of docetaxel or has used docetaxel in adjuvant/neo-adjuvant chemotherapy and has a relapse free survival of at least 12 months.~Exclusion Criteria:~* Pregnant or lactating females.~* History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety.~* Active or uncontrolled infection.~* Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure.~* Concomitant with brain metastases.~* Have received chemotherapy after metastasis.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm A (Type: ACTIVE_COMPARATOR): docetaxel and cisplatin chemotherapy
- arm B (Type: EXPERIMENTAL): docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
- arm C (Type: EXPERIMENTAL): docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years of age.~2. Has experienced continuous ischemic (cardiac) symptoms for at least 20 minutes.~3. Has onset of symptoms of qualifying acute MI within the past 24 hours, and planned for primary PCI. Patients presenting between 12 and 24 hours of symptom onset should still have an indication for primary PCI, i.e. persistent ischemic symptom and/or persistent or recurrent ST elevation~4. Has an ECG indicative of an acute STEMI showing:~   * ≥ 2 mm ST elevation in 2 or more contiguous precordial ECG leads (anterior infarction); or~  * ≥ 1 mm ST elevation in 2 or more contiguous limb ECG leads (other infarction); or~  * New or presumably new left bundle branch block (LBBB)~5. Shock patients are eligible (but not patients with prolonged cardiac arrest)~6. Be willing to provide informed consent (informed consent may be provided by a legally authorized representative if the patient is not able to provide it).~7. Agree to comply with all protocol-specified procedures, including protocol-mandated follow-up~Exclusion Criteria:~1. Use of UFH or LMWH or any other anticoagulant agent (Vit K antagonists, fondaparinux, bivalirudin) within 48 hours prior to randomization~2. Thrombolytic therapy within the previous 48 hours~3. Known or suspected pregnancy in women of childbearing potential~4. History of hypersensitivity or contraindication to heparin or LMWH~5. Contraindication to primary PCI or any excessive bleeding risk (e.g. recent surgery) or suspected active internal bleeding~6. Coexistent condition associated with a limited life expectancy at short term (e.g. advanced cancer)~7. Prolonged (\> 10 minutes) cardiopulmonary resuscitation (CPR)~8. Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Enoxaparin
- 2 (Type: ACTIVE_COMPARATOR): UFH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Children/juveniles, 2-17 years of age.~* Polyarticular-course juvenile idiopathic arthritis (pcJIA) ≥ 6 months duration.~* Active disease (≥ 5 active joints, ≥ 3 with limitation of motion).~* Inadequate response to or inability to tolerate methotrexate.~* Methotrexate, oral corticosteroids, and non-steroidal anti-inflammatory drugs (NSAID) at stable dose(at least 8, 4, and 2 weeks,respectively) prior to baseline.~* Biologics discontinued, between at least 1 and 20 weeks prior to baseline, depending on biologic.~Exclusion Criteria:~* Auto-immune, rheumatic disease or overlap syndrome other than pcJIA.~* Wheelchair bound or bedridden.~* Intra-articular, intramuscular, intravenous, or long-acting corticosteroids within 4 weeks prior to baseline.~* Disease-modifying anti-rheumatic drugs (DMARD) (other than methotrexate) within 4 weeks prior to baseline.~* Previous treatment with tocilizumab.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 10 mg/kg in patients weighing < 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
- Tocilizumab 8 mg/kg in patients weighing < 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
- Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo to tocilizumab intravenously every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologic diagnosis of WHO grade III or WHO grade IV high grade glioma~  * Newly diagnosed disease~* Meets the following criteria:~  * The patient must undergo leukapheresis for immunologic monitoring~* Tumor expression of EGFRvIII by immunohistochemistry (IHC) or polymerase chain reaction (PCR)~* No radiographic or cytologic evidence of leptomeningeal or multicentric disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status ≥ 80%~* Curran Group status of I-IV~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No conditions that will potentially confound the study results, including any of the following:~  * Active infection requiring treatment or an unexplained febrile (\> 101.5°F) illness~ * Known immunosuppressive disease or known HIV infection~ * Unstable or severe intercurrent medical conditions such as severe heart or lung disease~* No demonstrated allergy to TMZ~* Able to tolerate TMZ~  * TMZ-induced lymphopenia allowed~* No prior allergic reaction to daclizumab/basiliximab or its components~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No other conventional therapeutic intervention other than steroids, radiation, or temozolomide (TMZ) prior to enrollment~* No prior allogeneic solid organ transplantation~* No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies~* No corticosteroids at a dose above physiologic level except nasal or inhaled steroid at the time of first study vaccination~  * For the purposes of this study, physiologic dose is defined as \< 2 mg of dexamethasone/day~ * Once study vaccinations have been initiated, if patients subsequently require increased steroids, they are permitted to remain on the study~* No prior daclizumab/basiliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
- Arm II (Type: EXPERIMENTAL): Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
- Basiliximab (Type: EXPERIMENTAL): Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females \> 18 years of age~* Active PsA with \> 3 tender and \> 3 swollen joints despite standard therapy~* Unsatisfactory response or intolerance to at least one prior or ongoing DMARD (study enrollment must be in accordance with current national guidelines for treatment of PsA with TNF inhibitors)~* A negative serum pregnancy test (serum HCG) for women of childbearing potential prior to the start of treatment.~* Use of a reliable method of contraception by all female patients of childbearing potential~* Able and willing to self-administer sc injections or have a suitable person to administer sc injections~* Able and willing to give written informed consent and comply with the protocol~Exclusion Criteria:~* Prior treatment with any investigational agent within 30 days or five half lives of the product, whichever is longer~* Treatment within last 2 months with infliximab or within last 3 weeks with etanercept~* Treatment within last 4 weeks with a combination of MTX and leflunomide~* Treatment within last 4 weeks with a combination of cyclosporine with any other DMARD-Subject has received UVA phototherapy (including PUVA within 2 weeks prior to screening)~* History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin or cervical dysplasia~* History of or current active acute inflammatory joint disease of origin other than PsA~* Comorbidities (uncontrolled diabetes, unstable ischemic heart disease, CHF, active IBD, stroke within 3 months, chronic leg ulcer and other condition which would put subject at risk by participation in the protocol~* Positive serology for hepatitis B or C~* History of positive HIV status~* Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment~* Females who are pregnant or breast-feeding~* History of clinically significant drug or alcohol abuse in the last year~* Previous diagnosis or signs of central nervous system demyelinating diseases~* History of tuberculosis, histoplasmosis or listeriosis~* Subjects with latent TB or having other risk factors for activation of latent TB who have not initiated a TB prophylaxis prior to the first adalimumab treatment .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a refractory, metastatic, or unresectable histologically or cytologically confirmed solid malignant tumor with high tumor mutational burden (TMB-H) who are refractory to standard local therapies, or for which no standard treatment is available.~* Must be able to provide tissue and blood TMB-H testing results~* Must have measurable disease for response assessment~Exclusion Criteria:~* Participants with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) or hematological malignancy as primary site of disease~* Participants who received prior treatment with an anti-programmed death-1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1), anti-programmed death ligand 2 (anti-PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways~* Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 28 days of first administration of study treatment~Other protocol defined inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab Combination (Type: EXPERIMENTAL): None
- Nivolumab Monotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mutation in SLC2A1 gene~* Age \> 3 years~* Patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study~* Covered by french social security~* Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (In addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials)~Exclusion Criteria:~* Evidence of psychiatric disorder~* Attendant neurological disorder~* Comorbid medical condition that would render them unsuitable for the study, e.g. HIV, diabetes~* Pregnant or parturient or lactating women~* Unwillingness to be informed in case of abnormal MRI~* Failure to give written informed consent~* Unable to understand the protocol~* Unable to participate to the whole study~* Absence of signed informed consent~* Persons deprived of their liberty by judicial or administrative decision~* Person subject to an exclusion period for another research~* Subjects with exclusion criteria required by french law

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLUT1 DS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete